Human VEGF Receptor 2 ELISA Kit (ab213476)
- Datasheet
- References
- Protocols
Overview
-
Product nameHuman VEGF Receptor 2 ELISA Kit
See all VEGF Receptor 2 kits -
Detection methodColorimetric
-
Precision
Intra-assay Sample n Mean SD CV% Human serum 8 2.5% Inter-assay Sample n Mean SD CV% Human serum 3 5.8% -
Sample typeCell culture supernatant, Serum, Heparin Plasma, EDTA Plasma, Citrate Plasma
-
Assay typeSandwich (quantitative)
-
Sensitivity10 pg/ml
-
Range117 pg/ml - 7500 pg/ml
-
Recovery
Sample specific recovery Sample type Average % Range Cell culture supernatant 97 95% - 98% Serum 96 94% - 97% Heparin Plasma 97 95% - 99% EDTA Plasma 95 89% - 98% Citrate Plasma 114 109% - 122% -
Assay time1h 30m
-
Assay durationOne step assay
-
Species reactivityReacts with: Human
Does not react with: Mouse, Rat, Cow -
Product overview
Human VEGFR2 SimpleStep ELISA kit (ab192148) has been re-developed with new capture and detector antibodies. This new kit has the same name but a different product number (ab213476). We have identified new recombinant monoclonal antibodies to use in the SimpleStep ELISA platform that provide a higher sensitivity when quantification of VEGFR2 in human serum, plasma, cell culture supernatants, and cell culture extracts.
VEGF Receptor 2 in vitro SimpleStep ELISA® (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of VEGF Receptor 2 protein in serum, plasmas, and cell culture supernatant.
The SimpleStep ELISA® employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. TMB substrate is added and during incubation is catalyzed by HRP, generating blue coloration. This reaction is then stopped by addition of Stop Solution completing any color change from blue to yellow. Signal is generated proportionally to the amount of bound analyte and the intensity is measured at 450 nm. Optionally, instead of the endpoint reading, development of TMB can be recorded kinetically at 600 nm.
Sensitivity:
Samples in Sample Diluent NS: 41.6 pg/mL
Samples in Sample Diluent 3.75BS: 10 pg/mL
-
Notes
VEGF R2 (vascular endothelial growth factor receptor 2) is 1356 amino acids long and is a class III receptor tyrosine kinase. VEGF R2 acts as a cell surface receptor for VEGFA, VEGFC, and VEGFD, where binding of these VEGFs to VEGF R2 activates several signaling cascades, including activation of PLCG1 (leading to the activation of protein kinase C), the MAP kinase signaling pathways, and the AKT1 signaling pathway. Furthermore, VEGF R2 plays an essential role in the regulation of angiogenesis, vascular development and permeability, embryonic hematopoiesis, and reorganization of the actin cytoskeleton. Finally, VEGF R2 is a major growth factor for endothelial cells and is the main facilitator of VEGF-induced endothelial proliferation, differentiation, and migration.
-
Tested applicationsSuitable for: Sandwich ELISAmore details
-
PlatformPre-coated microplate (12 x 8 well strips)
Properties
-
Storage instructionsStore at +4°C. Please refer to protocols.
-
Components 1 x 96 tests 10X Human VEGF Receptor 2 Capture Antibody 1 x 600µl 10X Wash Buffer PT (ab206977) 1 x 20ml 20X Human VEGF Receptor 2 Detector Antibody 1 x 300µl ab221824 - Antibody Diluent 4BI 1 x 6ml Human VEGF Receptor 2 Lyophilized Recombinant Protein 2 vials Plate Seals 1 unit Sample Diluent NBS 1 x 2ml Sample Diluent NS 1 x 50ml SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit Stop Solution 1 x 12ml TMB Development Solution 1 x 12ml -
Research areas
-
FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
-
Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
-
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
Cellular localizationMembrane.
- Information by UniProt
-
Alternative names
- CD309
- CD309 antigen
- EC 2.7.10.1
see all -
Database links
- Entrez Gene: 3791 Human
- Omim: 191306 Human
- SwissProt: P35968 Human
- Unigene: 479756 Human
Associated products
-
SimpleStep ELISA kits
Applications
Our Abpromise guarantee covers the use of ab213476 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Sandwich ELISA | Use at an assay dependent concentration. |
Images
-
Example of human VEGF Receptor 2 standard curve in Sample Diluent NS.Background-subtracted data values (mean +/- SD) are graphed.
-
Example of human VEGF Receptor 2 standard curve in Sample Diluent 3.75BS.Background-subtracted data values (mean +/- SD) are graphed.
-
Interpolated concentrations of native VEGF Receptor 2 in human serum, plasma citrate, and plasma EDTA samples.The concentrations of VEGF Receptor 2 were measured in duplicate, interpolated from the VEGF Receptor 2 standard curves and corrected for sample dilution. Undiluted samples are as follows: serum 7.5%, plasma (citrate) 7.5%, and plasma (EDTA) 7.5%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean VEGF Receptor 2 concentration was determined to be 60 ng/mL in serum, 42 ng/mL in plasma (citrate) and 49 ng/mL in plasma (EDTA).
-
Interpolated concentrations of native VEGF Receptor 2 in human plasma heparin, and spiked recombinant VEGF Receptor 2 in HUVEC culture supernatant samples.The concentrations of VEGF Receptor 2 were measured in duplicate, interpolated from the VEGF Receptor 2 standard curve and corrected for sample dilution. Undiluted samples are as follows: plasma (heparin) 12.5% and HUVEC culture supernatant 80%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean VEGF Receptor 2 concentration was determined to be 44 ng/mL in plasma (heparin). Native signal of HUVEC culture supernatant at 80% was determined to be 0.4 ng/mL.
-
Serum from ten individual healthy human male donors was measured in duplicate.Serum from ten individual healthy human male donors was measured in duplicate. Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean VEGF Receptor 2 concentration was determined to be 2.37 ng/mL with a range of 1.19 – 3.23 ng/mL.
Protocols
References
ab213476 has not yet been referenced specifically in any publications.
